Drug Combination Details
| General Information of the Combination (ID: C88798) | |||||
|---|---|---|---|---|---|
| Name | Luteolin NP Info | + | CD55-TRAIL Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | ||
| SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | |||
| SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | |||
| In-vivo Model | A total of 8*106 HT-29 cells were injected subcutaneously into the right flank of female BALB/c nude mice (4 weeks old). | |||||
| Experimental
Result(s) |
The addition of luteolin enhanced oncolytic adenovirus-mediated enhanced green fluorescent protein, early region 1A and TRAIL expression, synergistically inhibited tumor growth and promoted CRC cellular apoptosis in vitro and in vivo, and significantly decreased cytotoxicity in lung/bronchial normal epithelial cells, compared with single treatment. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combination of oncolytic adenovirus and luteolin exerts synergistic antitumor effects in colorectal cancer cells and a mouse model. Mol Med Rep. 2017 Dec;16(6):9375-9382. | |||
